PALATINE, Ill., March 15, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Acura Pharmaceuticals, Inc. (OTCBB:ACUR) today announced results of Study AP-ADF-102 (“Study 102"), a phase II clinical trial for OxyADF (oxycodone HCl and niacin) Tablets, the Company’s lead product candidate incorporating its proprietary Aversion(r) (abuse deterrent) Technology. OxyADF Tablets are being developed pursuant to an investigational new drug application (“IND”) on file with the U.S. Food and Drug Administration (“FDA”) with an intended indication for treatment of moderate to moderately severe pain. The Company also provided a status update on the overall OxyADF Tablets development program and its proprietary Aversion(r) (abuse deterrent) Technology.
